In what could be a major breakthrough in fighting prostate cancer, a researcher from Gitam Institute of Technology (GIT) has found that a drug used for treating coronary heart disease and stroke can control the progression of this form of cancer.
Prostate cancer develops in the prostate, a gland in the male reproductive system, and is said to be among the top three types of cancers afflicting men apart from lung and gastric cancers. Patients suffering from prostate cancer have difficulty in urinating, feel the need to frequently pass urine and experience pain when passing urine.
Although a growing number of people today are stricken with cancer – the leading cause of death in France since 2004 – their risk of succumbing to this disease is dropping. Nationwide mortality rates continue to vary, most notably on a regional level, as was demonstrated in the distinguished Atlas de la mortalité par cancer en France metropolitaine [Atlas of cancer death in mainland France (excluding overseas territories)], published on January 28. On a generalized basis, the numbers for Northern and Central France clearly point to hypermortality while death rates in the southern portion of the country were lower
Cancer patients in remission at a Suffolk hospital can have their own cells transplanted back to them with the use of a new piece of equipment.
The stem-cell bath defrosts frozen cells taken from people recovering from blood cancers myeloma, leukaemia and lymphoma at Ipswich Hospital.
When transplanted back to the patient following treatment the cells can help their body create new bone marrow.
The bath cuts down on the need for patients to travel to other hospitals.
The stem cells are stored at -190C in liquid nitrogen and can be kept for several years at the national blood transfusion centre in Cambridge.
Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”, by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem’s methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.
As described in the patent, Pluristem’s therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat
Much to the dismay of patients and physicians, cancer stem cells — tiny powerhouses that generate and maintain tumor growth in many types of cancers — are relatively resistant to the ionizing radiation often used as therapy for these conditions. Part of the reason, say researchers at Stanford University School of Medicine, is the presence of a protective pathway meant to shield normal stem cells from DNA damage. When the researchers blocked this pathway, the cells became more susceptible to radiation.
“Our ultimate goal is to come up with a therapy that knocks out the cancer stem cells,” said Robert